Screener
Xenon Pharmaceuticals XENE Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Xenon Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338244
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Financing activities: | ||
| Proceeds from offerings, net | 837,526 | — |
| Proceeds from exercise of stock options | 5,513 | 1,216 |
| Net cash provided by financing activities | 843,039 | 1,216 |
| Effect of exchange rate changes on cash and cash equivalents | 132 | 568 |
| Decrease in cash and cash equivalents | (79,636) | (7,331) |
| Cash and cash equivalents, beginning of period | 199,163 | 142,712 |
| Cash and cash equivalents, end of period | $119,527 | $135,381 |
Item 1. Financial Statements
FAQ
- What is Xenon Pharmaceuticals's financing cash flow?
- Xenon Pharmaceuticals (XENE) reported financing cash flow of $26K in Q2 2026.
- How has Xenon Pharmaceuticals's financing cash flow changed year-over-year?
- Xenon Pharmaceuticals's financing cash flow decreased by 60.0% year-over-year, from $65K to $26K.
- What is the long-term trend for Xenon Pharmaceuticals's financing cash flow?
- Over 3 years (2021 to 2025), Xenon Pharmaceuticals's financing cash flow has grown at a -36.0% compound annual growth rate (CAGR), from $447.54M to $117.11M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Xenon Pharmaceuticals's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude